Lacosamid Ratiopharm

Lacosamide, the active ingredient in Lacosamid Ratiopharm, is an anticonvulsant presented as a tablet for oral use. It is employed to treat partial‑onset seizures in patients with epilepsy, frequently as adjunctive therapy to improve seizure control when other medications are insufficient, by stabilizing neuronal membranes through modulation of sodium channels.

GNH USA supplies Lacosamid Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Lacosamide is indicated for seizure disorders within the epilepsy disease family.

Partial‑onset seizures: used as adjunctive therapy to reduce seizure frequency in patients whose seizures are not fully controlled by other antiepileptic drugs. Focal epilepsy: helps achieve better seizure control when added to existing treatment regimens. Adjunctive therapy for epilepsy: improves overall seizure management as part of combination therapy.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Nausea - Fatigue

Serious or Rare Side Effects: - Cardiac arrhythmias (e.g., PR interval prolongation) - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or behavior

When prescribing Lacosamide, several safety considerations should be observed.

Renal function: assess baseline renal function and adjust dose if impairment is present. Hepatic function: monitor liver enzymes during therapy. Concomitant antiepileptic drugs: evaluate for possible dose adjustments. Pregnancy: use only if potential benefit justifies the risk to the fetus. Driving and operating machinery: avoid if experiencing dizziness or visual disturbances. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Lacosamide can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide plasma concentrations. - Co‑administration with other sodium‑channel blockers (e.g., lamotrigine): increased risk of central nervous system depression.

Moderate Interactions (Monitor Closely): - Oral contraceptives: lacosamide may decrease hormonal efficacy, consider alternative contraception. - Alcohol: may enhance dizziness and sedation. - Other antiepileptic drugs: dose adjustments may be required to maintain therapeutic effect.